%0 Journal Article
%T Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
%A Guanglei Zhuang
%A Hong-Zhuan Chen
%A Hui-Min Lei
%A Jiang-Kai Dong
%A Liang Zhang
%A Liang Zhu
%A Qian Liang
%A Shengzhe Zhang
%A Wen-Bin Li
%A Ya-Bin Tang
%A Yang Wang
%A Ye Zhou
%A Ying Shen
%A Yunguang Tong
%J Theranostics
%D 2018
%I Ivyspring International Publisher
%R 10.7150/thno.23177
%X How to improve the efficacy and reverse the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, remains a major challenge in the targeted therapy of lung adenocarcinoma with EGFR-activating mutation. Phosphoglycerate dehydrogenase (PHGDH) is the key enzyme of de novo serine biosynthesis over-expressed in various types of cancer including lung cancer. Elevated PHGDH expression is correlated with a worse overall survival in clinical lung adenocarcinoma patients. Here we investigated the role of PHGDH in lung adenocarcinoma with the acquisition of resistance to erlotinib.
%K phosphoglycerate dehydrogenase
%K erlotinib resistance
%K metabolic activity
%K epidermal growth factor receptor
%U http://www.thno.org/v08p1808.htm